|
注册号: Registration number: |
ChiCTR2600122341 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-13 08:38:25 |
|
注册时间: Date of Registration: |
2026-04-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
产后腹直肌分离个性化预防与管理策略探索 |
|
Public title: |
Exploration of individualized prevention and management strategies for separation of rectus abdominalis after delivery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
产后腹直肌分离个性化预防与管理策略探索 |
|
Scientific title: |
Exploration of individualized prevention and management strategies for separation of rectus abdominalis after delivery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
董小瑾 |
研究负责人: |
董小瑾 |
|
Applicant: |
Dong Xiaojin |
Study leader: |
Dong Xiaojin |
|
申请注册联系人电话: Applicant telephone: |
+86 10 82693141 |
研究负责人电话:
Study leader's |
+86 10 82693141 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18612401979@163.com |
研究负责人电子邮件: Study leader's E-mail: |
18612401979@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区中关村大街29号 |
研究负责人通讯地址: |
北京市海淀区中关村大街29号 |
|
Applicant address: |
No. 29, Zhongguancun Street, Haidian District, Beijing |
Study leader's address: |
No. 29, Zhongguancun Street, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京市海淀医院 |
||
|
Applicant's institution: |
Beijing Haidian Hospital |
||
|
研究负责人所在单位: |
北京市海淀医院 |
||
|
Affiliation of the Leader: |
Beijing Haidian Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)药/医伦审第(061-2)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京市海淀医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Beijing Haidian Hospital Medical Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-04 00:00:00 | ||
|
伦理委员会联系人: |
刘慧 |
||
|
Contact Name of the ethic committee: |
Liu Hui |
||
|
伦理委员会联系地址: |
北京市海淀区中关村大街29号 |
||
|
Contact Address of the ethic committee: |
No. 29, Zhongguancun Street, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 82693657 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
yaya23381@sina.com |
|
研究实施负责(组长)单位: |
北京市海淀医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Haidian Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区中关村大街29号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 29, Zhongguancun Street, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市海淀区卫生健康发展科研培育计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Haidian District Health Development Scientific Research Cultivation Plan |
||||||||||||||||||||||
|
研究疾病: |
产后腹直肌分离 |
||||||||||||||||||||||
|
Target disease: |
Postpartum diastasis rectus abdominis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探索针对产后多因素导致腹直肌分离预后不良的的个性化预防与管理新型模式,该管理新模式旨在实现产后腹直肌分离治疗的提前介入,探寻更为高效的管理策略,以优化腹直肌分离的治疗效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
Exploring a new personalized prevention and management model for poor prognosis of rectus abdominis diastasis caused by multiple factors postpartum. This new management model aims to achieve early intervention in the treatment of postpartum rectus abdominis diastasis and to explore more efficient management strategies to optimize the treatment outcomes of rectus abdominis diastasis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.腹疝; 2.腹部手术史、腹部或骨盆外伤史; 3.有使腹内压升高的疾病或病史(如慢性咳嗽); 4.未能完整配合完成治疗过程; 5.产后观察到明显脏器脱垂者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Abdominal hernia; 2. History of abdominal surgery or abdominal or pelvic trauma; 3. Presence of diseases or medical history that increase intra-abdominal pressure (such as chronic cough); 4. Failure to fully cooperate in completing the treatment process; 5. Obvious organ prolapse observed after childbirth. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2027-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-13 00:00:00 至 To 2027-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
课题组由专人采用统计软件随机分组产生随机数列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A random number series is randomly grouped by a special person using statistical software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |